Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV

Background. Tenofovir disoproxil fumarate (TDF) or its prodrug tenofovir alafenamide fumarate (TAF) are currently being recommended in treatment of HIV infection. Distinct pharmacological properties of these two forms of a this drug make TAF treatment less nephrotoxic and lead to better impact on b...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michał Łomiak, Zofia Gajek, Jan Stępnicki, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Poznan University of Medical Sciences 2023-09-01
coleção:	Journal of Medical Science
Assuntos:	antiretroviral therapy tenofovir disoproxil fumarate tenofovir alafenamide lipids cholesterol low-density lipoproteins
Acesso em linha:	https://jms.ump.edu.pl/index.php/JMS/article/view/808
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!